Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 801–900 of 1,000
Non-Alcoholic Fatty Liver Disease (NAFLD) and its Recent Therapeutic Strategies
Mishra, N. K., Mishra, A., & Priyadarshini, R. (2023) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2023.00022 · Cited by 3
Metabolic Dysfunction-associated Fatty Liver Disease: An Urgent Call for Global Action
Fernandez, C. J., Nagendra, L., & Pappachan, J. M. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.20.1.1 · Cited by 5
“13 This alarming rise in the prevalence of these metabolic disorders is expected to cause a substantial increase in liver-related morbidity, healthcare costs and mortality.”
BackgroundGummlich, B. P. M., Raddatz, D., & Gollisch, K. S. C. (2024) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2024.200247 · Cited by 3
Szalanczy, A., Sherrill, C., Fanning, K. M., Hart, B. P., Caudell, D. L., Davis, A. W., Whitfield, J. M., & Kavanagh, K. (2024) · Radiation Research · doi:10.1667/rade-23-00202.1 · Cited by 3
“Hepatic steatosis, the early stage of non-alcoholic fatty liver disease (MAFLD), has reached epidemic proportions in Western societies ( 17 – 20 ) and currently has few specific therapeutic options aside from weight loss and anti-diabetic medications.”
BackgroundSangeetha, A. D., & Prabhuswamy, K. M. (2019) · International Journal of Contemporary Medical Research [IJCMR] · doi:10.21276/ijcmr.2019.6.8.52 · Cited by 3
Pediatric type 2 diabetes mellitus complications: a systematic review of the literature
Jordan, D. N., & Jordan, J. L. (2012) · journal of Diabetes Research and Clinical Metabolism · doi:10.7243/2050-0866-1-24 · Cited by 3
“If left untreated, however, NAFLD is progressive and may ultimately lead to cirrhosis later in either childhood or adulthood [63,64].”
BackgroundInfluentialLiang, J., Gong, Y., Wang, Y., Qiu, Q., Zou, C., Dou, L., Liu, X., & Song, H. (2014) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-014-0136-9 · Cited by 3
Hatami, M. T., & Eftekhari, E. (2016) · Biotechnology and Health Sciences · doi:10.17795/bhs-36162 · Cited by 3
Caffeine with Links to NAFLD and Accelerated Brain Aging
Martins, I. J. (2018) · InTech eBooks · doi:10.5772/intechopen.70581 · Cited by 16
“Education programs such as food restriction programs (Figure 1) have been performed but induction of global NAFLD has not decreased in the world [7, 8].”
BackgroundHelicobacter pylori Infection and Hepatobiliary Pathology
German, S. V., & Bobrovnitsky, I. P. (2018) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2018-28-4-15-22 · Cited by 3
Study of non-alcoholic fatty liver disease in metabolic syndrome
Shaikh Mohammed Aslam, S., & Bhanuprakash, P. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20184758 · Cited by 3
Aspectos relevantes de la enfermedad por hígado graso no alcohólico
Hernández-Osorio, I. C., & Luján-Ramos, M. A. (2021) · Hepatología · doi:10.52784/27112330.137 · Cited by 3
Crum‐Cianflone, N. F. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ106 · Cited by 3
“In the current study [9], NASH was associated with “traditional” risk factors of obesity and insulin resistance, findings consistent with the literature [5, 6, 8, 10].”
ResultLeading-Edge Approaches for In Vitro Hepatotoxicity Evaluation
LeCluyse, E. L., Norona, L. M., Akingbasote, J. A., Howell, L. S., Woodhead, J. L., Cross, M. J., Roth, A. B., & Goldring, C. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64267-8 · Cited by 2
Ternovoy, S. K., Shiryaev, G. A., Ustyuzhanin, D. V., & Тинович, А. Д. (2018) · Medical Visualization · doi:10.24835/1607-0763-2018-4-50-58 · Cited by 2
Bhandary, R. R., Shetty, S., Rao, A. V., & Srikrishna, U. (2020) · International Journal of Clinical Biochemistry and Research · doi:10.18231/2394-6377.2018.0068 · Cited by 2
“As prevalence of NAFLD seems to be increasing day by day, it has become a matter of global concern.(1) NAFLD is widely considered to be the hepatic manifestation of metabolic syndrome.”
BackgroundBaduku, T. S., Ibinaiye, P. O., Igashi, J. B., Usman, B., Manko, M., Ahmad, A. E.-F., Tabari, A. M., Mustapha, S., Olarinoye-Akorede, A. S., & Balogun, M. S. (2024) · Journal of the Nigerian Academy of Medicine · doi:10.4103/jnam.jnam_4_23 · Cited by 2
Jin, D., Jin, S., Zhou, T., Sheng, G., Yao, M., Gao, P., & Li, G. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1786758 · Cited by 2
Kranidiotis, G., Angelidi, A. M., Sevdalis, E., Telios, T.-N., Gougoutsi, A., & Melidonis, A. J. (2013) · Clinics and Practice · doi:10.4081/cp.2013.e17 · Cited by 2
Ling, W., Quan, J.-R., Lin, J., Qiu, T., Li, J., Lu, Q., Lu, C., & Luo, Y. (2018) · EXPERIMENTAL ANIMALS · doi:10.1538/expanim.17-0124 · Cited by 2
“The worldwide prevalence of fatty liver (FL) has shown an increase recent changes in lifestyle [1].”
BackgroundSurgical Issues in NASH: Bariatric Surgery and Liver Transplantation
Paul, S., & Charlton, M. (2018) · Current Hepatology Reports · doi:10.1007/s11901-018-0429-3 · Cited by 2
Role of silymarin in the management of non-alcoholic fatty liver disease: Time to clear the mist
Roy, K., & Lyer, U. (2019) · Bioactive Compounds in Health and Disease · doi:10.31989/bchd.v2i5.622 · Cited by 2
“Abbreviations: NAFLD, Non-alcoholic fatty liver disease; NASH, Non-alcoholic steatohepatitis, HCC, Hepatocellular carcinoma, ROS, Reactive oxygen species; CVD, Cardiovascular disease; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; SAMe, S-Adenosyl-L-Methionine; RCT, Randomized controlled trial Competi…”
BackgroundInfluentialBharath, R., & Rajalakshmi, P. (2019) · URSI Asia-Pacific Radio Science Conference · doi:10.23919/ursiap-rasc.2019.8738717 · Cited by 2
Efficacy of orlistat in the treatment of patients with non-alcoholic fatty liver
Alamdari, M. I., Habibzadeh, S., Azami, A., Shirinzadeh, B., Aslanian, R., & Yazdanbod, K. (2020) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20200179 · Cited by 4
Nonalcoholic Fatty Liver Diseases in Newly Analyzed Diabetes Mellitus Patients with Risk Factors
Ismail, A., Anjum, J., Bhatti, H. U. R., Bhutto, M. A., Azam, M., & Masood, A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs22164570 · Cited by 2
Mendes, G., da Silva, P. H. S., Gonçalves, P. V. P., de Lima, E. M. M., & Vianna, A. R. D. C. B. (2023) · Brazilian Journal of Biology · doi:10.1590/1519-6984.276465 · Cited by 2
Anokhina, H. A., Харченко, В. В., Korulia, I. A., & Yakubovskaya, I. A. (2014) · GASTROENTEROLOGY · doi:10.22141/2308-2097.3.53.2014.82132 · Cited by 2
Lavekar, A. S., Satyanarayana, P. T., & Lavekar, A. (2019) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20195481 · Cited by 2
Chaves, G. V., de Souza, D. S., Pereira, S., Saboya, C. J., & Peres, W. A. F. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70197-5 · Cited by 2
Association of non-alcoholic fatty liver disease and coronary artery disease
Majumder, B., Tandel, V., Ghosh, S., & Chatterjee, S. (2016) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20163293 · Cited by 2
Evolution of the determinants of chronic liver disease in Quebec
Sanabria, A., Dion, R., Lucar, E., & Soto, J. (2013) · Chronic diseases and injuries in Canada · doi:10.24095/hpcdp.33.3.04 · Cited by 5
“Further studies will be necessary to add to the body of knowledge on obesity as a risk factor for other CLDs, such as non-alcoholic fatty liver.(4,28,29)”
Zaki, M. E., Yousef, W., Kamal, S., Mohamed, R., Saleh, O. M., & Ezzat, W. M. (2018) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1477 · Cited by 2
Thompson, D. S., Tennant, I. A., Soares, D., Osmond, C., Byrne, C. D., Forrester, T., & Boyne, M. S. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00138 · Cited by 2
“Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in Western countries [1], and it is rapidly becoming the most common liver disease worldwide [2].”
BackgroundDas, D. C., Alam, S., Noor-E-Alam, S. M., Kamal, M., Mollah, F. H., & Mamun-Al-Mahtab, M.-A.-M. (2019) · Bangabandhu Sheikh Mujib Medical University Journal · doi:10.3329/bsmmuj.v12i3.43327 · Cited by 2
Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Nowicki, J., & Pizzorno, J. E. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00200-4 · Cited by 3
Kohda, Y. (2020) · Fundamental Toxicological Sciences · doi:10.2131/fts.7.291 · Cited by 2
“…obesity and diabetes are risk factors for non-alcoholic fatty liver disease (NAFLD) (Adams and Angulo, 2005; Adams, 2007; Moscatiello et al., 2007; Lazo and Clark, 2008; Argo and Caldwell, 2009; Bellentani and Marino, 2009; Cusi, 2009; Arrese, 2010; Porepa et al., 2010; Bellentani et al., 2010).”
Moise, C. G., Donoiu, I., Târtea, G.-C., Mirea, O., & Rogoveanu, I. (2021) · PubMed Central · doi:10.12865/chsj.47.02.19 · Cited by 3
“the myocardial function either globally or regionally, is based on the recognition on the two-dimensional image of speckles (essentially a myocardial wall imprint), and dynamic tracking of each point identified, throughout the cardiac cycle, by a series of successive ultrasound frames [2].”
BackgroundYang, S., Chen, X., Chen, S., Chen, H., Zhao, Y. M., Wu, Z., Luo, H., & Zhang, Z. (2022) · NMR in Biomedicine · doi:10.1002/nbm.4875 · Cited by 2
“The prevalence of NAFLD is estimated globally as 24%, and it exceeds 30% in South America and the Middle East.1,2 NAFLD is usually asymptomatic and reversible at its early stage; however, it can evolve into nonalcoholic steatohepatitis (NASH) and liver cirrhosis, which is rarely reversible.1,3 The astronomical healthc…”
BackgroundJouenne, A., Hamici, K., Varlet, I., Sourdon, J., Daudé, P., Lan, C., Kober, F., Landrier, J., Bernard, M., & Desrois, M. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.089 · Cited by 2
Frequency of Dyslipidemia in Non-Alcoholic Fatty Liver Disease Patients
Kiran, A., Nasir, N. U., & Jamil, M. I. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v1i2.1935 · Cited by 2
Novel 3D Approach to Model Non-Alcoholic Fatty Liver Disease using human Pluripotent Stem CellsPreprint
Morell, C. M., Tilson, S. G., Tomaz, R. A., Shahsavari, A., Munteanu, A., Canu, G., Wesley, B. T., Perrin, M., Geti, I., Mukhopadhyay, S., et al. (2024) · eLife · doi:10.7554/elife.95042 · Cited by 3
Impact of Endocrine Disorders on the Liver
Ciaula, A. D., Christidis, G., Krawczyk, M. J., Lammert, F., & Portincasa, P. (2020) · Endocrinology · doi:10.1007/978-3-319-66362-3_6-1 · Cited by 1
The Mechanism of Nonalcoholic Fatty Liver Disease Induced by Helicobacter pylori Infection
李, 婷. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.119566 · Cited by 1
A Conversation about Healthy Eating
Lesica, N. A. (2017) · UCL Press eBooks · doi:10.14324/111.9781911576754 · Cited by 1
Lichtler, R., Klossner, H., Smith, N., Hoyo, C., & Cowley, M. (2025) · FASEB BioAdvances · doi:10.1096/fba.2025-00045 · Cited by 1
Elmansy, N., Ali, A. W., Gadalla, A. A. E. H., Hashem, M. B., Sehemy, L. A., Gaber, Y., Yosry, A., & Elnafrawy, M. S. (2026) · The Egyptian Journal of Radiology and Nuclear Medicine · doi:10.1186/s43055-026-01706-2 · Cited by 1
“One of the most common causes of elevated liver enzymes is non-alcoholic fatty liver disease (NAFLD); it is also a crucial predisposing factor for chronic liver disease [1].”
Sharma, A. N., Bhagavatula, H., Mapundu, M. T., & Chimusa, E. R. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1803957 · Cited by 1
Lee, M.-S., Shin, Y., Jung, S., Kim, C., Kim, I.-H., & Kim, Y. (2015) · Journal of Food and Nutrition Research · doi:10.12691/jfnr-3-1-7 · Cited by 1
“Approximately 20-30% of adults in western countries are estimated to have nonalcoholic hepatic disease [3].”
BackgroundRisks and Predictors of Non-Alcoholic Liver Disease Progression Using Association Rules Mining
Gameel, T. A., Rady, S., & Kamal, S. M. (2020) · International Journal of Online and Biomedical Engineering (iJOE) · doi:10.3991/ijoe.v16i06.13629 · Cited by 1
Impact of Endocrine Disorders on the Liver
Ciaula, A. D., Christidis, G., Krawczyk, M. J., Lammert, F., & Portincasa, P. (2020) · Endocrinology · doi:10.1007/978-3-319-68729-2_6 · Cited by 2
Innate Immunity and Disorders of the Liver
Heikenwälder, M. F., Knolle, P. A., & Protzer, U. (2013) · Springer eBooks · doi:10.1007/978-3-319-02096-9_6 · Cited by 1
Metabolic Steatosis & Fibrosis: Review of the Non-Invasive Tools for Diagnosis and Screening
Miette, V., Abdennour, M., Sandrin, L., & Sasso, M. (2011) · InTech eBooks · doi:10.5772/20794 · Cited by 2
Omega-3 polyunsaturated fatty acids for non-alcoholic fatty liver disease
Lin, S., Xiao, K., Liu, Y., Su, P., Chen, P., Zhang, Y., & Bai, Y. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010838 · Cited by 1
RetractedNon-alcoholic steatohepatitis (NASH) and oral lichen planus: a rare occurrence
Conrotto, D., Bugianesi, E., Chiusa, L., & Carrozzo, M. (2010) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2010.11.001 · Cited by 1
The impact of genetic variability on liver disease in the Hispanic/Latin-American population
Lau-Corona, D., Kershenobich, D., & Gutiérrez‐Reyes, G. (2011) · Autoimmunity · doi:10.3109/08916934.2011.592883 · Cited by 1
“The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide [7].”
BackgroundGuthrie, J. D. (2012) · Journal of diagnostic medical sonography · doi:10.1177/8756479312458033 · Cited by 1
n-3 LCPUFA in the reversal of hepatic steatosis: the role of ACOX and CAT-1
Tapia, G., Gonzalez‐Mañán, D., D’Espessailles, A., & Dossi, C. G. (2016) · Grasas y Aceites · doi:10.3989/gya.0886152 · Cited by 1
Kuryata, O. V., & Grechanyk, M. M. M. (2015) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2015.1.38626 · Cited by 1
Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment
Maconi, G., Furfaro, F., Fries, W., Dell’Era, A., Bezzio, C., Costantino, G., Giuliano, V., Alibrandi, A., Guzowski, T., & Bassotti, G. (2016) · Liver International · doi:10.1111/liv.13198 · Cited by 1
Non-Pharmacological Treatment for Non Alcoholic Fatty Liver DiseaseA Review
Tha, T. P. (2016) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v4i8.61 · Cited by 1
Mahmoudi, T., Nobakht, H., Dabiri, R., Maleki, I., Dehghan, P., Mansour‐Ghanaei, F., Derakhshan, F., & Zali, M. R. (2016) · Meta Gene · doi:10.1016/j.mgene.2016.10.012 · Cited by 2
Cardiovascular Disease and NASH
de Siqueira, É. R. F., Pereira, L. M. M. B., & Sanyal, A. J. (2015) · Liver Research - Open Journal · doi:10.17140/lroj-1-107 · Cited by 1
Conversation about Healthy Eating
Lesica, N. A. (2017) · UCL Press eBooks · doi:10.2307/j.ctt1rfzxmw · Cited by 2
Agrawal, P. K., Kumar, M. T., Verma, V. K., Singh, A. K., Nim, R. K., Pious, T., & Singh, P. K. (2017) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20173703 · Cited by 1
“Central obesity, type 2 diabetes mellitus, hypertension and dyslipidemia are the main risk factors of NAFLD.(4,5) The diagnosis of NAFLD requires a combination of invasive and non-invasive tests.”
InfluentialРоль эндотелиальной дисфункции в патогенезе гепатостеатоза у детей
Варламова, Н. Н., Sinelnikova, Y. V., Solodkova, I. V., Chasnyk, V. G., & Зиновьева, Е. Н. (2016) · ТЕНДЕНЦИИ РАЗВИТИЯ НАУКИ И ОБРАЗОВАНИЯ · doi:10.18411/lj2016-8-1-03 · Cited by 1
Progress in Research on Nonalcoholic Fatty Liver and Gestational Diabetes
Luo, Z., & Wu, Q. (2019) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2019.104019 · Cited by 1
“DOI: 10.4236/ijcm.2019.104019 Apr. 4, 2019 251 International Journal of Clinical Medicine Keywords Nonalcoholic Fatty Liver Disease, Gestational Diabetes Mellitus, Tumor Necrosis Factor, Leptin, Estrogen”
BackgroundInfluentialPrevalence ratio of free fatty acid in obese group with non-alcoholic fatty liver disease
Handayani, R., Purnamaningsih, S. M., & Sukorini, U. (2019) · Journal of the Medical Sciences (Berkala Ilmu Kedokteran) · doi:10.19106/jmedsci005102201906 · Cited by 1
Effect of Gardenia Jasminoides on Insulin Resistance Induced by Non-alcoholic Fatty Liver Disease
Seo, I.-B., Ahn, S. H., Jeong, H. S., & Kim, K. (2019) · 동의생리병리학회지 · doi:10.15188/kjopp.2019.10.33.5.288 · Cited by 1
Kudaravalli, P., & John, S. (2019) · StatPearls · Cited by 1
Colon dysbiosis, increasing of intestinal wall permeability and non-alcohol fatty liver disease
Uspensky, Y. P., Baryshnikova, N. V., & Балукова, Е. В. (2020) · Medical alphabet · doi:10.33667/2078-5631-2019-4-38(413)-48-53 · Cited by 1
Mustafa, G. (2019) · Academic Journal of Gastroenterology & Hepatology · doi:10.33552/ajgh.2019.01.000509 · Cited by 1
“Although NAFLD is more common in subject with obesity and diabetes mellitus (DM), it also occurs in lean and non-diabetic subject [3,4,5].”
BackgroundOLTEANU, V.-A., Bălan, G. G., Gîlcă-Blanariu, G.-E., Timofte, O., Mitrică, D., Diaconescu, S., Bălan, G. G., & Ștefănescu, G. (2020) · ROMANIAN BIOTECHNOLOGICAL LETTERS · doi:10.25083/rbl/25.1/1289.1295 · Cited by 1
“Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of a metabolic syndrome and is the first cause of chronic hepatic disease being recognized as a leading cause of liver-related morbidity and mortality in many developed countries worldwide (MARCHESINI & al [1]; ANSTEE & al [2]; MCPHERSON…”
BackgroundPrevalence and structure of fatty liver disease of varying etiology at the rural therapeutic stretch
Mikhailova, N. V., & Петрунько, И. Л. (2020) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-176-4-65-71 · Cited by 1
A zsírdús étrend indukálta steatosis és a bél–máj tengely változásai
Blázovics, A., Sipos, P., Kocsis, I., Fébel, H., Kleiner, D., Szentmihályi, K., & Fehér, E. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.31786 · Cited by 1
PREVALENCE OF NAFLD AMONG HEALTHY LIVER DONORS
Shawl, M. R., Mir, F. U. I., Rahman, S. A., Anand, A. C., Wadhawan, M., & Gupta, S. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/8024686 · Cited by 1
TG: HDL, AST: ALT, A:G Ratios in Alcoholic and Non-alcoholic Fatty Liver patients
Manish, A., Bharosay, A., Negi, K., & Srivastava, R. (2024) · Journal of Research in Applied and Basic Medical Sciences · doi:10.61186/rabms.10.3.279 · Cited by 1
Symmetric dimethylguanidino valeric acid, a novel single biomarker of hepatic steatosis
Rodionov, R. N., Jarzebska, N., Koay, Y. C., Li, M., Kühn, M., Bornstein, S. R., Martens‐Lobenhoffer, J., Eslam, M., Chen, F., Rubets, E., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111366 · Cited by 1
The Role of Glycans in Chronic Inflammatory Gastrointestinal and Liver Disorders and Cancer
Fernandes, Â., Dias, A. M., Silva, M. C., Gaifem, J., Azevedo, C. M., Carballo, I., & Pinho, S. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00036-5 · Cited by 1
Journal of Gastrointestinal Disorders and Liver function
(2019) · Journal of Gastrointestinal Disorders and Liver Functions · doi:10.15436/2471-0601 · Cited by 1
Indicators of Inflammation in the Fasting Induced Fatty Liver of the American Mink (Neovison vison)
McConkey, S., Patterson, D. M., Parsons, V. R. L., Rouvinen‐Watt, K., & applicable, N. (2012) · Library and Archives Canada (Government of Canada) · Cited by 1
Lang, A. L. (2018) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2965 · Cited by 1
Slizgi, J. R. (2017) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/v0kz-1a18 · Cited by 1
Yang, Y., Tian, C., Dai, J., Zhang, W., Shu-qing, L., Xiang, M., Wang, Y., & Cao, J. (2020) · doi:10.21203/rs.3.rs-15691/v1 · Cited by 1
Pi, Z., Wang, M., Lin, H., Guo, Y., Chen, S., Diao, X., Xia, H., Liu, G., Zeng, J., Zhang, X., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-111720/v1 · Cited by 1
Yang, Y., Tian, C., Dai, J., Zhang, W., Li, S., Min, X., Wang, Y., & Cao, J. (2020) · doi:10.21203/rs.3.rs-15691/v3 · Cited by 1
Novel 3D Approach to Model Non-Alcoholic Fatty Liver Disease using human Pluripotent Stem CellsPreprint
Morell, C. M., Tilson, S. G., Tomaz, R. A., Shahsavari, A., Munteanu, A., Canu, G., Wesley, B. T., Perrin, M., Geti, I., Mukhopadhyay, S., et al. (2024) · eLife · doi:10.7554/elife.95042.1 · Cited by 3
Stone, L. C. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham)
Mazo, D. F. D. C. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-05042012-093828
Future watch: Evolving trends in the management of nonalcoholic steatohepatitis
Sanyal, A. J. (2015) · Clinical Liver Disease · doi:10.1002/cld.477
Studies on the mechanisms of action and physiological relevance of SOCS proteins
Zadjali, F. (2011) · Figshare
Nonalcoholic Steatohepatitis in Children: The Modern Day Pediatric Epidemic
El-Shabrawi, M. H. F., & Issa, M. (2015) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2015.04.512
Endoplasmic Reticulum Stress and Lipophagy in Nonalcoholic Steatohepatitis
Wu, J., & Shen, X. (2014) · Austin Journal of Gastroenterology
Ogawa, K., Ohmoto‐Sekine, Y., Hara, S., Okuda, C., Amakawa, K., Arimoto, S., Kato, H., Hsieh, S. D., Tanabe, M., Ogata, C., et al. (2012) · Ningen dock : official journal of the Japanese Society of Human Dry Dock · doi:10.11320/ningendock.27.561 · Cited by 1
Importance of iron overload and steatosis in patients with chronic liver disease
Marmur, J. (2014) · Figshare
Dubuquoy, C. (2012) · theses.fr (ABES) · doi:10.70675/c6364335z5556z453cz8cb2z5c28558d79b6 · Cited by 1
“La prévalence du NAFLD est de 20 à 30 % dans la population générale des pays industrialisés et la stéatose hépatique est le plus souvent bénigne (Bellentani et al., 2010 ; Hooper et al., 2011).”
BackgroundGuthrie, J. D., Sheikh, M. Y., Morrell, S., & Neal, D. (2012) · Journal of diagnostic medical sonography · doi:10.1177/8756479312450617
Chabanova, E., Bille, D. S., Thisted, E., Holm, J., & Thomsen, H. S. (2012) · Journal of Biomedical Graphics and Computing · doi:10.5430/jbgc.v3n1p35
Nonalcoholic Steatohepatitis Animal Model, Induced by High-Fat Diet and Tetracycline
Areshidze, D. A., Timchenko, L. D., Syomin, I. A., Kozlova, M., & Rzhepakovsky, I. V. (2014) · Modern Applied Science · doi:10.5539/mas.v9n1p170 · Cited by 1
Results of a fast-track referral system for urgent outpatient hepatology visits
Milana, M., Santopaolo, F., Lenci, I., Francioso, S., & Baiocchi, L. (2015) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzv011
Emerging roles for biomaterials in the treatment of liver disease
Hammond, J. S., & Lobo, D. N. (2012) · Expert Review of Medical Devices · doi:10.1586/erd.11.70
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.